1
Up to 24.2% mean body weight reduction after 48 weeks in a Phase 2 trial published in the New England Journal of Medicine.
View on PubMed →
VIP 002 Retatrux EU
Tax included where applicable. Shipping calculated at checkout.
Retatrutide is a first-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data published in the New England Journal of Medicine showed up to 24.2% mean body weight reduction in 48 weeks. Phase 3 TRIUMPH trials demonstrated average weight loss of 71.2 lbs and up to 82% reduction in liver fat.
Every batch is independently tested by a 3rd party laboratory. Certificate of Analysis available below.
The more you buy, the more you save
Buy 5
-5%
discount
Buy 7
-7.5%
discount
BEST DEAL
Buy 10+
-10%
discount
Every batch is tested by an independent third-party laboratory with no commercial relationship to Camo Chem. We never self-certify. The full Certificate of Analysis is published on this page and verifiable directly with the testing lab.
Worldwide shipping. UK orders typically delivered in 1-3 working days. EU and international orders 3-7 working days. Tracked and signed-for delivery. Free shipping over £65 (UK) / €110 (EU) / $110 (US).
Store lyophilised powder in a cool, dry place. After reconstitution, refrigerate at 2-8°C.
Don't forget
Bacteriostatic water
Required for reconstituting lyophilised peptides. European Warehouse.
Reconstitution
Need help with dosing?
Calculate the exact volume of bacteriostatic water for your target dose.
Worldwide ShippingUK · EU · USA · Asia
3rd Party TestedIndependent lab CoA
≥98% HPLC PurityVerified per batch
Safe DeliveryDiscreet packaging
Research Overview
About this compound
What does the research say?
Retatrutide is a single-molecule triple agonist that simultaneously activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. This triple mechanism represents the next generation beyond dual agonists like tirzepatide.
In a Phase 2 trial published in the New England Journal of Medicine, retatrutide achieved up to 24.2% mean body weight reduction after 48 weeks. In the Phase 3 TRIUMPH-4 trial, the highest dose produced an average weight loss of 71.2 lbs. Additionally, 72% of participants with prediabetes at baseline reverted to normoglycemia. A separate study demonstrated up to 82% reduction in liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
These are not marketing claims. These are peer-reviewed, published results. You can verify every reference below.
Why does quality matter?
Retatrutide is a complex peptide with triple receptor activity. The balance between GIP, GLP-1, and glucagon receptor activation is critical to its unique pharmacological profile. Impure or degraded material may activate receptors unevenly, producing an unpredictable response.
At Camo Chem, every batch is tested by an independent 3rd party laboratory. We publish the full Certificate of Analysis for every batch, and you can verify the results directly with the lab. We do not self-certify. Ever.
Ask your current supplier: who tests their products?
Technical Data
Compound specifications
| Common Names | Retatrutide, LY3437943 |
| CAS Number | 2381089-83-2 |
| Classification | Triple GIP/GLP-1/Glucagon receptor agonist |
| Purity | ≥98% (HPLC verified) |
| Content per Vial | 10 mg |
| Physical Form | Lyophilised (freeze-dried) white powder |
| Solubility | Soluble in water and bacteriostatic water |
| Storage | Powder: cool, dry place. After reconstitution: 2-8°C. |
Peer-reviewed Studies
Published research on Retatrutide
2
Phase 3 TRIUMPH-4 trial: average weight loss of 71.2 lbs with the highest dose, with substantial osteoarthritis pain relief.
View on PubMed →3
Up to 82% reduction in liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
View on PubMed →
Customer Reviews
What researchers are saying
5.0
7 reviews
5★
7
4★
0
3★
0
2★
0
1★
0
★★★★★
Ottimo prodotto lo consiglio
★★★★★
So far so good, I have used 2 different brands and find CamoChem stronger than the other. 👍🏽
FAQ
Frequently asked questions
Retatrutide is a first-in-class triple hormone receptor agonist with CAS number 2381089-83-2. It simultaneously activates GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials. This product is sold exclusively as a research compound.
Semaglutide is a GLP-1 mono-agonist. Retatrutide activates three receptors simultaneously (GIP + GLP-1 + glucagon), which is believed to produce stronger metabolic effects through complementary pathways. Phase 2 data showed greater weight reduction with retatrutide than has been reported with GLP-1 mono-agonists.
Every batch meets a minimum of 98% purity as verified by HPLC. Testing is performed by an independent 3rd party laboratory.
Yes. Retatrutide is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use.
In lyophilised form, store in a cool, dry place. After reconstitution, refrigerate at 2-8°C.
